FOLLOW the MONEY: $ 12 million (hints at big REVENUE)As a shareholder I torn between two choices:
(a) Look at the chart, look at the developments and come to a conclusion that MEDV is a failure.
or,
(b) Follow the money, ignore the chart and developments and, come to a conclusion that MEDV is successful.
Shareholders are selling their stock because they are in the dark and have concluded that option (a) applies.
But, insiders are loading up on the stock some $ 12 millionn because they have concluede that option (b) applies.
For myself, I have learned to follow the MONEY TRAIL even though there is no visibility at this moment for the shareholders.
I have to trust that Stan Bharti and his associates would not throw away $ 12 million if they did not have a place of action or, vision to ensure that they will get their month back and, more.
David Preiner is very quiet but he is not idle. He will not talk hot air like Doug did. He is organizing his vision of the future with MEDV.
This is what I have understood that they are doing at the moment:
They started with covid19 testing to establish a base of clients and, a base of outlets where you can get tested. They have now expanded their product offerings to include: adxit test score, vaccines, issuance of medication through a pharmacy, mobile health care using Artificial intelligence and delivered through the Myosin app (a health care platform) which they purchased to have doctors treat patients, to funding blowfish through tests and then launching product around USA with all employers.
You can see that they have expanded their product platforms and beyond covid19 towards mobile health care.
Because it will encompass many services, the revenue generated per patient will be in the $ 300 to $ 500 per year, which means you will need less patients to survive and, also that gross margins will be through the roof.
As David said, their service will be a one stop shopping as if you go to Star Bucks or, Tim Hortons.
Q2 is a transmational period however for Q3 that ends September 2021 we will see a strong balance sheet with good revenue numbers which will only accelerate by Q4.
Treat this investment as an RRSP purchase at the moment, meaning put your shares away and look at them in 6 months. Then you have reconsider your position.
mpo